Kırşehir Ahi Evran University School of Medicine, Department of Ophthalmology, Kırşehir, Turkey.
Kırşehir Ahi Evran Training and Research Hospital, Department of Ophthalmology, Kırşehir, Turkey.
Photodiagnosis Photodyn Ther. 2022 Sep;39:102996. doi: 10.1016/j.pdpdt.2022.102996. Epub 2022 Jul 2.
To evaluate choroidal vascularity index (CVI) after a single dose of intravitreal dexamethasone implant in refractory diabetic macular oedema (DME).
Total choroidal area, luminal area, and CVI were measured at baseline, 1st month, and at 3rd month after dexamethasone implant using binarization of enhanced depth imaging optical coherence tomography (EDI-OCT) images.
A total of 25 eyes of 25 patients (mean age: 61.4 ± 8.3 years; 12 males, 13 females), were enroled in the study. All eyes had been previously treated with intravitreal aflibercept injections (mean number of injections 4.6 ± 2.5). Mean CVI was 70.3 ± 8.1 prior to intravitreal dexamethasone treatment. It was decreased to 66.1 ± 9.3 at 1 month and 63.5 ± 10.1 at 3 months after treatment. The mean CVI was significantly decreased at 3 months compared with pre-treatment measures (p = 0.033).
CVI was found to be decreased in patients who responded to intravitreal dexamethasone implant.
评估单次玻璃体内注射地塞米松植入物治疗难治性糖尿病性黄斑水肿（DME）后的脉络膜血管指数（CVI）。
使用增强深度成像光学相干断层扫描（EDI-OCT）图像的二值化，在基线、第 1 个月和第 3 个月测量总脉络膜面积、管腔面积和 CVI。
本研究共纳入 25 例 25 只眼（平均年龄：61.4±8.3 岁；男性 12 例，女性 13 例），所有患者均曾接受过玻璃体内注射阿柏西普治疗（平均注射次数 4.6±2.5 次）。玻璃体内注射地塞米松治疗前 CVI 平均值为 70.3±8.1。治疗后 1 个月降至 66.1±9.3，3 个月降至 63.5±10.1。与治疗前相比，治疗 3 个月后的 CVI 平均值显著降低（p=0.033）。
对玻璃体内注射地塞米松植入物有反应的患者 CVI 降低。
